# HMOX1

Source: https://onco.cc/targets/hmox1/  
OnCo record `hmox1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.

## Summary

Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron.

CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Sorafenib and Sunitinib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: heme oxygenase 1; Heme oxygenase 1; bK286B10; HO-1
- Tags: cancer-genes-wave
- Symbol: HMOX1
- Class: enzyme
- Biology: Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Location: Endoplasmic reticulum membrane (UniProt). Locus 22q12.3 (HGNC).
- Where found: Renal cell carcinoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:5013: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5013
- UniProt P09601: https://www.uniprot.org/uniprotkb/P09601/entry
- NCBI Gene 3162: https://www.ncbi.nlm.nih.gov/gene/3162
- Ensembl ENSG00000100292: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100292

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/hmox1.json